New long-term data from the DanGer Shock RCT

confirms the survival benefit of the Impella CP® heart pump increases year-over-year.*1
Learn More about DanGer Shock

The U.S. Food and Drug Administration (FDA) has determined Impella is safe and effective for its intended uses.

  • 1,500+

    Peer reviewed clinical studies have published on Impella, including DanGer Shock RCT published in the New England Journal of Medicine

  • 17

    Clinical Guidelines and Consensus statements

  • 400,000+

    Patients have been treated with Impella heart pumps

For Interventional Cardiologists

For Interventional Cardiologists

Treat high-risk PCI, cardiogenic shock and right heart failure patients

Learn More
For Cardiac and Vascular Surgeons

For Cardiac and Vascular Surgeons

Escalate, stabilize and recover native organs with minimally-invasive surgical techniques

Learn More
For Nurses

For Nurses

Use calculators, watch quick skills videos and learn patient management best practices

Explore Resources
For Fellows

For Fellows

Advance your knowledge and develop skills to treat complex PCI patients

Explore Resources

For Referring Providers

Are you caring for patients with heart disease? Learn more about how Impella heart pumps work, the benefits of Protected PCI with Impella and explore patient identification resources. 

Learn More

Native Heart and Lung Recovery

Conditions & Therapies

Access education, clinical evidence and practice support for Protected PCI, AMI cardiogenic shock, right heart failure, surgical applications and severe lung failure.

Learn More

Products & Services

Learn about the latest technology and how that technology may best support your patient.

Learn More

Education & Resources

Abiomed provides a comprehensive training program for health care providers.

Learn More

Subscribe to receive the latest clinical data and priority access to resources.

References

*Compared to standard care with STEMI in cardiogenic shock.

  1. Møller J, et al.  Long Term Outcomes of the DanGer Shock Trial  N Engl J Med 2025. 
  2. Møller, J., et al. (2024). Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock. N Engl J Med.
  3. Abiomed. (2024, September 13). Retrieved from PubMed search: “(Impella) AND ("Impella"[All Fields] AND 2000/01/01:2024/09/12[epdat]).
  4. Lawton, J. S. et al. (2021). 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. https://doi.org/10.1161/CIR.0000000000001038
  5. Chieffo, A. et al. (2021). 2021 Joint EAPCI/ACVC expert consensus document on percutaneous ventricular assist devices. EuroIntervention. https://eurointervention.pcronline.com/doi/10.4244/EIJY21M05_01
  6. Riley, R. et al. (2020). 2020 SCAI position statement on optimal percutaneous coronary interventional therapy for complex coronary artery disease. Catheter Cardiovasc Interv. DOI: 10.1002/ccd.28994
  7. Amsterdam, E. et al. (2014). 2014 Guideline for the Management of Patients with non-ST elevation ACS. Circulation. DOI: 10 .1161 /CIR .0000000000000134
  8. O'Gara, P. et al. (2013). 2013 ACCF/AHA Guideline for the Management of STEMI. Circulation. http://dx.doi.org/10.1016/j.jacc.2012.11.019
  9. Levine, G. et al. (2011). 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. J Am Coll Cardiol. doi:10.1016/j.jacc.2011.08.007
  10. Bernhardt, A. et al. (2023).  2023 ISHLT/ HFSA Guidelines on Acute MCS. J Heart and Lung Transplantation https://doi.org/10.1016/j.healun.2022.10.028.
  11. Heidenreich, P. et al. (2022). 2022 AHA/ACC/HFSA Guideline for Management of HF. J Am Coll Cardiol. https://doi.org/10.1016/j.jacc.2021.12.012
  12. McDonagh, T. et al. (2021). 2021 ESC Guidelines Acute and Chronic Heart Failur. Eur Heart J.  doi:10.1093/eurheartj/ehab368
  13. Chieffo, A. et al. (2021). 2021 EAPCI/ACVC Expert Consensus on pVAD. EuroIntervention. DOI: 10.4244/EIJY21M05_01
  14. Lorusso, R. et al. (2020). 2020 EACTS/ELSO/STS/AATS expert consensus on post-cardiotomy extracorporeal life support in adult patients. Eur J Cardiothorac Surg. doi:10.1093/ejcts/ezaa283
  15. Cronin, E. et al. (2019). 2019 HRS/EHRA/APHRS?LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. Heart Rhythm. doi:10.1093/ejcts/ezaa283
  16. Peura, J. et al. (2012). Recommendations for the use of MCS. Circulation. doi:10.1093/ejcts/ezaa283
  17. Tamis-Holland, J. et al. (2024) SCAI Expert Consensus Statement on the Management of Patients with STEMI Referred for Primary PCI. JSCAI. https://www.jscai.org/article/S2772-9303(24)01740-X/fulltext
  18. Vrints, C. et al. (2024) 2024 ESC Guidelines for the management of chronic coronary syndromes. EHJ. https://academic.oup.com/eurheartj/article/45/36/3415/7743115?login=false
  19. Schäfer, A. et al. (2024) Consensus Statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI). EuroIntervention; 20:e1-e14 DOI: 10.4244/EIJ-D-23-01100
  20. Rao, SV, et al. (2025). ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients with Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology. https://pubmed.ncbi.nlm.nih.gov/40013746/

NPS-1309

This information is intended for use by customers, patients, and healthcare professionals in [region] only. We recognize that the Internet is a global communications medium; however, laws, regulatory requirements, and product information for medical products can vary from country to country. The product information included here may not be appropriate for use outside [region], and the information from other sites you visit may not be appropriate for use in [region].

The Protected PCI community
is now on HeartRecovery.com

Providing education and training to help health care professionals
recover hearts, oxygenate the body and save lives.
Explore Now